Cadherin 6 Is a New RUNX2 Target in TGF-β Signalling Pathway

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Sancisi, Valentina ^a   Gandolfi, Greta ^a   Ragazzi, Moira ^a   Nicoli, Davide ^a   Tamagnini, Ione ^a   Piana, Simonetta ^a   Ciarrocchi, Alessia ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CADHERIN 6; RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; PROTEIN EXPRESSION; RNA EXTRACTION; SIGNAL TRANSDUCTION; THYROID CARCINOMA; THYROID CELL; TUMOR INVASION; WESTERN BLOTTING;

ALTERNATIVE SPLICING; CADHERINS; CARCINOMA; CELL LINE; CORE BINDING FACTOR ALPHA 1 SUBUNIT; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASMS; PHENOTYPE; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84884196738     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075489     Document Type: Article

References (42)

1. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, et al. (2007) Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J Cell Physiol 213: 374-383. doi:10.1002/jcp.21223. PubMed: 17680632.
2. Thiery JP, Acloque H, Huang RY, Nieto MA, (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890. doi:10.1016/j.cell.2009.11.007. PubMed: 19945376.
3. Kalluri R, (2009) EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119: 1417-1419. doi:10.1172/JCI39675. PubMed: 19487817.
4. Kalluri R, Weinberg RA, (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428. doi:10.1172/JCI39104. PubMed: 19487818.
5. Polyak K, Weinberg RA, (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 9: 265-273. doi:10.1038/nrc2620. PubMed: 19262571.
6. Foroni C, Broggini M, Generali D, Damia G, (2012) Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev 38: 689-697. doi:10.1016/j.ctrv.2011.11.001. PubMed: 22118888.
7. Nollet F, Kools P, van Roy F, (2000) Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. J Mol Biol 299: 551-572. doi:10.1006/jmbi.2000.3777. PubMed: 10835267.
8. Ciarrocchi A, Piana S, Valcavi R, Gardini G, Casali B, (2011) Inhibitor of DNA binding-1 induces mesenchymal features and promotes invasiveness in thyroid tumour cells. Eur J Cancer. 47: 934-945. doi:10.1016/j.ejca.2010.11.009. PubMed: 21146400.
9. Cho EA, Patterson LT, Brookhiser WT, Mah S, Kintner C, et al. (1998) Differential expression and function of cadherin-6 during renal epithelium development. Development. 125: 803-812. PubMed: 9449663.
10. Inoue T, Chisaka O, Matsunami H, Takeichi M, (1997) Cadherin-6 expression transiently delineates specific rhombomeres, other neural tube subdivisions, and neural crest subpopulations in mouse embryos. Dev Biol 183: 183-194. doi:10.1006/dbio.1996.8501. PubMed: 9126293.
11. Inoue YU, Asami J, Inoue T, (2008) Cadherin-6 gene regulatory patterns in the postnatal mouse brain. Mol Cell Neurosci 39: 95-104. doi:10.1016/j.mcn.2008.05.020. PubMed: 18617008.
12. Mah SP, Saueressig H, Goulding M, Kintner C, Dressler GR, (2000) Kidney development in cadherin-6 mutants: delayed mesenchyme-to-epithelial conversion and loss of nephrons. Dev Biol 223: 38-53. doi:10.1006/dbio.2000.9738. PubMed: 10864459.
13. Jia L, Liu F, Hansen SH, Ter Beest MB, Zegers MM, (2011) Distinct roles of cadherin-6 and E-cadherin in tubulogenesis and lumen formation. Mol Biol Cell. 22: 2031-2041. doi:10.1091/mbc.E11-01-0038. PubMed: 21508319.
14. Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, et al. (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLOS Med 5: e232. doi:10.1371/journal.pmed.0050232. PubMed: 19053170.
15. Paul R, Ewing CM, Robinson JC, Marshall FF, Johnson KR, et al. (1997) Cadherin-6, a cell adhesion molecule specifically expressed in the proximal renal tubule and renal cell carcinoma. Cancer Res 57: 2741-2748. PubMed: 9205085.
16. Shimazui T, Oosterwijk E, Akaza H, Bringuier P, Ruijter E, et al. (1998) Expression of cadherin-6 as a novel diagnostic tool to predict prognosis of patients with E-cadherin-absent renal cell carcinoma. Clin Cancer Res 4: 2419-2424. PubMed: 9796973.
17. Paul R, Necknig U, Busch R, Ewing CM, Hartung R, et al. (2004) Cadherin-6: a new prognostic marker for renal cell carcinoma. J Urol 171: 97-101. doi:10.1097/01.ju.0000101512.47242.79. PubMed: 14665853.
18. Fabien N, Fusco A, Santoro M, Barbier Y, Dubois PM, et al. (1994) Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer 73: 2206-2212. doi:10.1002/1097-0142(19940415)73:8. PubMed: 8156527.
19. Tanaka J, Ogura T, Sato H, Hatano M, (1987) Establishment and biological characterization of an in vitro human cytomegalovirus latency model. Virology 161: 62-72. doi:10.1016/0042-6822(87)90171-1. PubMed: 2823470.
20. Estour B, Van Herle AJ, Juillard GJ, Totanes TL, Sparkes RS, et al. (1989) Characterization of a human follicular thyroid carcinoma cell line (UCLARO82W-1). Virchows Arch B Cell Pathol Incl Mol Pathol 57: 167-174. doi:10.1007/BF02899078. PubMed: 2570483.
21. Saiselet M, Floor S, Tarabichi M, Dom G, Hébrant A, et al. (2012) Thyroid cancer cell lines: an overview. Front Endocrinol 3: 133. doi:10.3389/fendo.2012.00133.
22. Zeisberg M, Neilson EG, (2009) Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119: 1429-1437. doi:10.1172/JCI36183. PubMed: 19487819.
23. Nagaharu K, Zhang X, Yoshida T, Katoh D, Hanamura N, et al. (2011) Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol 178: 754-763. doi:10.1016/j.ajpath.2010.10.015. PubMed: 21281808.
24. Calì G, Gentile F, Mogavero S, Pallante P, Nitsch R, et al. (2012) CDH16/Ksp-cadherin is expressed in the developing thyroid gland and is strongly down-regulated in thyroid carcinomas. Endocrinology. 153: 522-534. doi:10.1210/en.2011-1572. PubMed: 22028439.
25. Massagué J, (2012) TGFβ signalling in context. Nat Rev Mol Cell Biol; 13: 616-630. doi:10.1038/nrm3434. PubMed: 22992590.
26. Heldin CH, Vanlandewijck M, Moustakas, (2012) A Regulation of EMT by TGFβ in cancer. FEBS Lett 586: 1959-1970. doi:10.1016/j.febslet.2012.02.037. PubMed: 22710176.
27. Vasko V, Espinosa AV, Scouten W, He H, Auer H, et al. (2007) Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A 104: 2803-2808. doi:10.1073/pnas.0610733104. PubMed: 17296934.
28. Cheung PY, Yip YL, Tsao SW, Ching YP, Cheung AL, (2011) Id-1 induces cell invasiveness in immortalized epithelial cells by regulating cadherin switching and Rho GTPases. J Cell Biochem 112: 157-168. doi:10.1002/jcb.22911. PubMed: 21053361.
29. Niu DF, Kondo T, Nakazawa T, Oishi N, Kawasaki T, et al. (2012) Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas. Lab Invest 92: 1181-1190. doi:10.1038/labinvest.2012.84. PubMed: 22641097.
30. Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, et al. (2002) SB-431542 is a potent and specific inhibitor of Transforming Growth Factor-b superfamily type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5 and ALK7. Mol Pharmacol 62: 65-74. doi:10.1124/mol.62.1.65. PubMed: 12065756.
31. Sancisi V, Borettini G, Maramotti S, Ragazzi M, Tamagnini I, et al. (2012) Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas. J Clin Endocrinol Metab, 97: E2006-E2015. PubMed: 22821892.
32. Endo T, Ohta K, Kobayashi T, (2008) Expression and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells. J Clin Endocrinol Metab 93: 2409-2412. doi:10.1210/jc.2007-2805. PubMed: 18381576.
33. Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, et al. (2011) Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res 13: R127. doi:10.1186/bcr3073. PubMed: 22151997.
34. Puxeddu E, Knauf JA, Sartor MA, Mitsutake N, Smith EP, et al. (2005) RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocr Relat Cancer. 12: 319-334. doi:10.1677/erc.1.00947. PubMed: 15947106.
35. Thiery JP, Sleeman JP, (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142. doi:10.1038/nrm1835. PubMed: 16493418.
36. Bastid J, (2012) EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev 31: 277-283. doi:10.1007/s10555-011-9344-6. PubMed: 22215472.
37. Klymkowsky MW, Savagner P, (2009) Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 174: 1588-1593. doi:10.2353/ajpath.2009.080545. PubMed: 19342369.
38. Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, et al. (2009) The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 69: 8317-8325. doi:10.1158/0008-5472.CAN-09-1248. PubMed: 19861538.
39. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, et al. (2012) Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene, 32: 3286-95. doi:10.1038/onc.2012.334. PubMed: 22847613.
40. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, et al. (2009) A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell. 15: 489-500. doi:10.1016/j.ccr.2009.03.022. PubMed: 19477428.
41. Jechlinger M, Podsypanina K, Varmus H, (2009) Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction. Genes Dev 23: 1677-1688. doi:10.1101/gad.1801809. PubMed: 19605689.
42. Huber MA, Kraut N, Beug H, (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558. doi:10.1016/j.ceb.2005.08.001. PubMed: 16098727.